The sole question on appeal was whether it would have been obvious to make zolmitriptan into a nasal spray. The Federal Circuit agreed with the district court that the prior art taught away from formulating zolmitriptan for intranasal administration.
The post Nasal Spray Patents Covering Migraine Drug Zomig Not Invalid As Obvious appeared first on IPWatchdog.com | Patents & Patent Law.
Nasal Spray Patents Covering Migraine Drug Zomig Not Invalid As Obvious
No Comments
Patent
- Enablement
- Fee Shifting
- Litigation
- Gathering Business Data? Be Careful, Mom is Watching – A Comment on Data Scraping and the Compulife Case
- Recent Trademark Developments: Four Cases Shaping the Law in the United States and Beyond
- Other Barks & Bites for Friday, September 18: USPTO Announces COVID-19 Provisional Patent Pilot, Copyright Office Issues MMA Ruling and China Issues Draft Patent Linkage Measures
- Squire Patton Boggs Is Seeking to Hire a Patent Attorney or Agent
- Tech Companies’ Lawsuit Against USPTO, Small Business Inventors’ Motion to Intervene Highlight Need to Address NHK-Fintiv Factors Via Rulemaking
Recent Posts
- Gathering Business Data? Be Careful, Mom is Watching – A Comment on Data Scraping and the Compulife Case
- Recent Trademark Developments: Four Cases Shaping the Law in the United States and Beyond
- Other Barks & Bites for Friday, September 18: USPTO Announces COVID-19 Provisional Patent Pilot, Copyright Office Issues MMA Ruling and China Issues Draft Patent Linkage Measures
- Squire Patton Boggs Is Seeking to Hire a Patent Attorney or Agent
- Tech Companies’ Lawsuit Against USPTO, Small Business Inventors’ Motion to Intervene Highlight Need to Address NHK-Fintiv Factors Via Rulemaking